201 related articles for article (PubMed ID: 25549870)
21. In vitro-in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans.
Shi M; Dong Y; Bouwmeester H; Rietjens IMCM; Strikwold M
Arch Toxicol; 2022 Aug; 96(8):2361-2380. PubMed ID: 35604418
[TBL] [Abstract][Full Text] [Related]
22. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
23. Physiologically based kinetic modeling of the bioactivation of myristicin.
Al-Malahmeh AJ; Al-Ajlouni A; Wesseling S; Soffers AE; Al-Subeihi A; Kiwamoto R; Vervoort J; Rietjens IM
Arch Toxicol; 2017 Feb; 91(2):713-734. PubMed ID: 27334372
[TBL] [Abstract][Full Text] [Related]
24. Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic: example: methyleugenol, CASRN: 93-15-2.
Smith B; Cadby P; Leblanc JC; Setzer RW
Food Chem Toxicol; 2010 Jan; 48 Suppl 1():S89-97. PubMed ID: 20113858
[TBL] [Abstract][Full Text] [Related]
25. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach.
Nong A; Krishnan K
Regul Toxicol Pharmacol; 2007 Jun; 48(1):93-101. PubMed ID: 17367907
[TBL] [Abstract][Full Text] [Related]
26. Immunochemical detection of covalently modified protein adducts in livers of rats treated with methyleugenol.
Gardner I; Bergin P; Stening P; Kenna JG; Caldwell J
Chem Res Toxicol; 1996 Jun; 9(4):713-21. PubMed ID: 8831815
[TBL] [Abstract][Full Text] [Related]
27. Metabolism, variability and risk assessment.
Dorne JL
Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
[TBL] [Abstract][Full Text] [Related]
28. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk.
Rietjens IM; Boersma MG; van der Woude H; Jeurissen SM; Schutte ME; Alink GM
Mutat Res; 2005 Jul; 574(1-2):124-38. PubMed ID: 15914212
[TBL] [Abstract][Full Text] [Related]
29. The natural basil flavonoid nevadensin protects against a methyleugenol-induced marker of hepatocarcinogenicity in male F344 rat.
Alhusainy W; Williams GM; Jeffrey AM; Iatropoulos MJ; Taylor S; Adams TB; Rietjens IM
Food Chem Toxicol; 2014 Dec; 74():28-34. PubMed ID: 25218219
[TBL] [Abstract][Full Text] [Related]
30. Use of Markov Chain Monte Carlo analysis with a physiologically-based pharmacokinetic model of methylmercury to estimate exposures in US women of childbearing age.
Allen BC; Hack CE; Clewell HJ
Risk Anal; 2007 Aug; 27(4):947-59. PubMed ID: 17958503
[TBL] [Abstract][Full Text] [Related]
31. Metabolism of methyleugenol in liver microsomes and primary hepatocytes: pattern of metabolites, cytotoxicity, and DNA-adduct formation.
Cartus AT; Herrmann K; Weishaupt LW; Merz KH; Engst W; Glatt H; Schrenk D
Toxicol Sci; 2012 Sep; 129(1):21-34. PubMed ID: 22610610
[TBL] [Abstract][Full Text] [Related]
32. An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants.
Valcke M; Krishnan K
Toxicology; 2011 Aug; 286(1-3):36-47. PubMed ID: 21605617
[TBL] [Abstract][Full Text] [Related]
33. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide.
Ploemen JP; Wormhoudt LW; Haenen GR; Oudshoorn MJ; Commandeur JN; Vermeulen NP; de Waziers I; Beaune PH; Watabe T; van Bladeren PJ
Toxicol Appl Pharmacol; 1997 Mar; 143(1):56-69. PubMed ID: 9073592
[TBL] [Abstract][Full Text] [Related]
34. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
35. Formation of hepatic DNA adducts by methyleugenol in mouse models: drastic decrease by Sult1a1 knockout and strong increase by transgenic human SULT1A1/2.
Herrmann K; Engst W; Meinl W; Florian S; Cartus AT; Schrenk D; Appel KE; Nolden T; Himmelbauer H; Glatt H
Carcinogenesis; 2014 Apr; 35(4):935-41. PubMed ID: 24318996
[TBL] [Abstract][Full Text] [Related]
36. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans.
El-Masri HA; Bell DA; Portier CJ
Toxicol Appl Pharmacol; 1999 Aug; 158(3):221-30. PubMed ID: 10438655
[TBL] [Abstract][Full Text] [Related]
37. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
38. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats.
Punt A; Paini A; Boersma MG; Freidig AP; Delatour T; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
Toxicol Sci; 2009 Aug; 110(2):255-69. PubMed ID: 19447879
[TBL] [Abstract][Full Text] [Related]
39. Incorporation of the genetic control of alcohol dehydrogenase into a physiologically based pharmacokinetic model for ethanol in humans.
Sultatos LG; Pastino GM; Rosenfeld CA; Flynn EJ
Toxicol Sci; 2004 Mar; 78(1):20-31. PubMed ID: 14718645
[TBL] [Abstract][Full Text] [Related]
40. Use of physiologically based kinetic (PBK) modeling to study interindividual human variation and species differences in plasma concentrations of quercetin and its metabolites.
Boonpawa R; Moradi N; Spenkelink A; Rietjens IM; Punt A
Biochem Pharmacol; 2015 Dec; 98(4):690-702. PubMed ID: 26441251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
